Interim Executive Director appointed ahead of search for permanent replacement
Geneva, 24 May 2016 — After four years at the helm of Médecins Sans Frontières’ advocacy and campaigning unit, the Access Campaign, Dr Manica Balasegaram will step down from his position of Executive Director at the end of May.
Dr Balasegaram will leave the Access Campaign having overseen a team of people who have worked on lowering the price of vaccines through the Fair Shot campaign, on improving access for drugs and diagnostics to manage hepatitis C, TB and HIV, and on highlighting the need to fix our current system of research and development for new drugs and diagnostics. Dr Balasegaram has also been involved in important health policy discussions around AMR, emerging infectious diseases and on access to medicines more broadly, including being part of the Expert Advisory group for the UN High Level Panel on Access to Medicines.
Dr Balasegaram will be joining the Global Antibiotic Research and Development (GARD) Partnership, an initiative spearheaded by Drugs for Neglected Diseases initiative and World Health Organization to develop new antibiotic treatments and to promote their responsible use, while ensuring access for all in need. He will take up this new post in early June.
Ahead of a search for a permanent replacement for Dr Balasegaram, MSF has appointed Sophie Delaunay as interim Executive Director. Ms Delaunay was the former Executive Director of MSF USA and currently heads MSF’s effort to advance knowledge sharing on Ebola and emerging pathogens. She will serve in this interim role for the next six months, based between MSF’s Geneva and New York offices.